Uterine Leiomyoma (Uterine Fibroids) Therapeutic Pipeline H1 2015 Review Research Report

News provided by

Mar 06, 2015, 11:45 ET

DALLAS, March 6, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2015" therapeutic market research report of 95 pages with latest updates, data and information to its online business intelligence library.

The report Uterine Leiomyoma (Uterine Fibroids) Pipeline Review H1 2015 provides an overview of the Uterine Leiomyoma (Uterine Fibroids)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Uterine Leiomyoma (Uterine Fibroids), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and special features on late-stage and discontinued projects.

Uterine fibroids are tumors that grow in a woman's womb (uterus). Uterine fibroids are noncancerous growths of the uterus that often appear during childbearing years. While many women do not experience any problems, symptoms can be severe enough to require treatment. Almost 70% to 80% of women will have fibroids by age 50. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods, pelvic pressure or pain, frequent urination, difficulty emptying bladder, constipation and backache or leg pains.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies discussed in this report include: AbbVie Inc., Bayer AG, BioSpecifics Technologies Corp., Dongkook Pharmaceutical Co., Ltd., Euroscreen S.A., Kissei Pharmaceutical Co., Ltd., Laboratoire HRA Pharma, Neurocrine Biosciences, Inc., Novartis AG, Repros Therapeutics Inc., Takeda Pharmaceutical Company Limited. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=308865 . (This is a premium report priced at US$2000 for a single user License.)

Drugs profile discussed in this report include: collagenase clostridium histolyticum, Drug to Activate Progesterone Receptor for Uterine Fibroids, Drug to Antagonize GnRH Receptor for Endometriosis and Uterine Leiomyoma, elagolix sodium, ESN-364, EVE-104, KLH-2109, LFA-102, mifepristone, relugolix, Small Molecule to Antagonize GnRH for Endometriosis, Uterine Fibroids, and Oncology, telapristone acetate, triptorelin pamoate biosimilar, ulipristal acetate, vilaprisan.

Featured News & Press Releases cover by this report include: Mar 27, 2013: Neurocrine Biosciences Initiates Phase IIb Study Of Elagolix For Treatment Of Uterine Fibroids; Feb 28, 2013: Repros Announces FDA Grants End Of Phase II Meeting To Discuss Proellex-V Phase III Study Design; Jan 03, 2013: Repros Reports Positive Topline Results From Phase II Study Of Proellex-V For Treatment Of Uterine Fibroids; Jul 30, 2012: FDA Schedules Meeting With Repros To Discuss Phase II Protocol For Proellex For Treatment Of Endometriosis; Jul 23, 2012: Repros's Proellex-V Shows Consistent Efficacy In Phase II Study Of Uterine Fibroids; Apr 30, 2012: Repros's Proellex-V Clears Hurdle In Uterine Fibroid Program; Mar 12, 2012: Watson Initiates US Phase III Clinical Trial Of Esmya; Feb 27, 2012: HRA Pharma's Esmya Receives European Commission Marketing Authorization For Pre-Operative Treatment Of Uterine Fibroids; Feb 02, 2012: PregLem Announces Full Results Of PEARL I And II Studies Of Esmya Published In New England Journal Of Medicine; Jan 04, 2012: FDA Accepts Repros's Investigational New Drug Application For Proellex-V For Treatment Of Uterine Fibroids.

Global Markets Direct reports feature investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by an expert team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids)
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports of Cancer Drugs at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/cancer-drugs .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us:

G+ / Google Plus:https://plus.google.com/u/0/104156468549256253075/

Twitter:https://twitter.com/RnRMR

Facebook:http://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds:http://www.rnrmarketresearch.com/feed

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
[email protected]

SOURCE RnR Market Research